Scholars Central

Research articlePublished 19 Dec 2024

Association of New Inflammatory Markers Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte (MCVL) with Anti PD-1 Antibody Nivolumab Treatment Response in Metastatic Renal Cell Carcinoma

Authors: Heves Surmeli, Deniz Isik, Hamit Bal, Salih Tunbekici, Oguzcan Kinikoglu, Yunus Emre Altintas, Goncagul Akdag, Sedat Yildirim

Chemotherapy: Open Access

Volume 12 · Issue 4 · Pages 1–7

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Kidney cancer is an immunogenic tumor and inflammation plays a role in tumor formation and progression. The aim of this study was to investigate the effect of biochemical markers in predicting treatment response in patients with metastatic Renal Cell Carcinoma (RCC) receiving nivolumab treatment. Methods: Patients aged ≥ 18 years who received nivolumab treatment for metastatic RCC between February, 2022 and January, 2024 were evaluated. Cellular blood count was evaluated at the diagnosis of metastatic disease and periodically during nivolumab treatment. We measured the cell count in peripheral blood at admission and calculated the inflammation indices obtained from the blood cell count as follows: MCVL (Mean Corpuscular Volume/Lymphocytes) and IIC ((mean corpuscular volume *width of erythrocyte distribution* neutrophils/(lymphocytes*1000)). Results: The study included 99 patients. The mean age of the patients was 58.32 ± 11.95 (19-87). 75.8% of the patients had clear cell and 8.1% had papillary type pathology. When the disease control status was evaluated at 3 months after nivolumab treatment, it was seen that 48 patients had partial response and 18 patients remained stable. The 3rd month Disease Control Rate (DCR) was 68.7%. When the ICIC and MCVL rates of the patients were examined, it was determined that the ICC and MCVL values of the patients who showed progression were higher (p=0.038 for ICC, p=0.040 for MCVL). The ICC cut-off value was determined as 15.50. With this cut-off value, disease control can be predicted with 77% sensitivity and 64% specificity (AUC: 0.743 CI 95% (0.647-0.838); p<0.001). MCVL cut-off value was determined as 65.15. This cut-off value can predict disease control with 65% sensitivity and 61% specificity (AUC: 0.674, CI: 95% (0.564-0.783), p=0.006). Conclusion: Cumulative Inflammatory Index (ICC) and MCVL have a significant effect on disease-free survival and overall survival in predicting success of nivolumab treatment for metastatic renal cell carcinoma.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalChemotherapy: Open Access
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Heves Surmeli”
  • BylineArticles whose byline prints “Deniz Isik”
  • BylineArticles whose byline prints “Hamit Bal”
  • BylineArticles whose byline prints “Salih Tunbekici”
  • BylineArticles whose byline prints “Oguzcan Kinikoglu”
  • BylineArticles whose byline prints “Yunus Emre Altintas”
  • BylineArticles whose byline prints “Goncagul Akdag”
  • BylineArticles whose byline prints “Sedat Yildirim”